Back to search

Article

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal

2024-02-01

Abstract excerpt

DNA hypomethylating agents (HMAs) are used to treat acute myeloid leukemia (AML) and myelodysplasia patients who are unsuitable for intensive chemotherapy. However, low response rates and therapy-resistant relapse remain significant challenges. To improve outcomes, we must understand how AML cells survive HMA treatment and continue to proliferate following therapy. We combine single-cell multiomics with parallel c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
de30b364-fb88-5a09-90c2-30ebd96d72a5
DOI
10.1101/2024.01.30.577864
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewalDOI 10.1101/2024.01.30.577864
Multi-omics reveals azacitidine partially restores the hematopoiesis-supportive functions in mesenchymal stromal cells from patients with chronic myelomonocytic leukemiaSemantic proximity
Single cell multiomics reveal clonal and functional dynamics of MDS stem/progenitor cells during hypomethylating therapySemantic proximity
Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic SyndromesSemantic proximity
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapySemantic proximity
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.Semantic proximity
Azacytidine restores T cell function in AML by modulating DNA methylationSemantic proximity
Non-genetic heterogeneity, altered cell fate and differentiation therapy.Semantic proximity
Multi-omics analysis of AML cells treated with azacitidine reveals highly variable cell surface proteome remodelingSemantic proximity
Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteomeSemantic proximity
Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selectionSemantic proximity
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.